form_type
stringclasses 2
values | accession_number
stringlengths 20
20
| filing_date
stringlengths 14
14
| quarter_ending
stringclasses 172
values | company_name
stringlengths 5
54
| text
stringlengths 101
2.42k
| entities
listlengths 1
18
|
|---|---|---|---|---|---|---|
10-Q | 0001628280-23-016716 | 20230509125247 | 20230331 | Stagwell Inc | Revenue and net income attributable to Wolfgang, included within the three months ended March 31, 2023 Unaudited Consolidated Statements of Operations was $1.1 million and $0.2 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 159,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 156,
"start_date_for_period": "2023-01-01",
"value": 1100000
},
{
"currency_/_unit": "USD",
"end_character": 176,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 173,
"start_date_for_period": "2023-01-01",
"value": 200000
}
] |
10-Q | 0001628280-23-016716 | 20230509125247 | 20230331 | Stagwell Inc | Revenue and net income attributable to Epicenter, included within the three months ended March 31, 2023 Unaudited Consolidated Statements of Operations was $1.1 million and $0.6 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 160,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 157,
"start_date_for_period": "2023-01-01",
"value": 1100000
},
{
"currency_/_unit": "USD",
"end_character": 177,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 174,
"start_date_for_period": "2023-01-01",
"value": 600000
}
] |
10-Q | 0001368365-23-000046 | 20230522163257 | 20230331 | REMARK HOLDINGS, INC. | During the three months ended March 31, 2023 and 2022, we recognized approximately $0.1 million and $2.2 million, respectively, of revenue from the relationship with the China Business Partner. At March 31, 2023 and December 31, 2022, in addition to the outstanding accounts receivable balances from the China Business Partner described in | [
{
"currency_/_unit": "USD",
"end_character": 87,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 84,
"start_date_for_period": "2023-01-01",
"value": 100000
},
{
"currency_/_unit": "USD",
"end_character": 104,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 101,
"start_date_for_period": "2022-01-01",
"value": 2200000
}
] |
10-Q | 0000794170-23-000043 | 20230601161141 | 20230430 | Toll Brothers, Inc. | In the three-month periods ended April 30, 2023 and 2022, we purchased land from unconsolidated entities, principally related to our acquisition of lots from our Land Development Joint Ventures, totaling $52.4 million and $14.1 million, respectively. In the six-month periods ended April 30, 2023 and 2022, we purchased land from unconsolidated entities, principally related to our acquisition of lots from our Land Development Joint Ventures, totaling $69.1 million and $37.9 million, respectively. Our share of income from the lots we acquired was insignificant in each period. In the three-month periods ended April 30, 2023 and 2022, we sold land to unconsolidated entities, which principally involved land sales to our Rental Property Joint Ventures, totaling $8.2 million and $73.9 million, respectively. In the six-month periods ended April 30, 2023 and 2022, we sold land to unconsolidated entities, which principally involved land sales to our Rental Property Joint Ventures, totaling $8.2 million and $151.9 million, respectively. These amounts are included in “Land sales and other revenue” on our Condensed Consolidated Statements of Operations and Comprehensive Income and are generally sold at or near our land basis. | [
{
"currency_/_unit": "USD",
"end_character": 209,
"end_date_for_period": "2023-04-30",
"label": "revenues",
"start_character": 205,
"start_date_for_period": "2023-02-01",
"value": 52400000
},
{
"currency_/_unit": "USD",
"end_character": 227,
"end_date_for_period": "2022-04-30",
"label": "revenues",
"start_character": 223,
"start_date_for_period": "2022-02-01",
"value": 14100000
},
{
"currency_/_unit": "USD",
"end_character": 458,
"end_date_for_period": "2023-04-30",
"label": "revenues",
"start_character": 454,
"start_date_for_period": "2022-11-01",
"value": 69100000
},
{
"currency_/_unit": "USD",
"end_character": 476,
"end_date_for_period": "2022-04-30",
"label": "revenues",
"start_character": 472,
"start_date_for_period": "2021-11-01",
"value": 37900000
},
{
"currency_/_unit": "USD",
"end_character": 769,
"end_date_for_period": "2023-04-30",
"label": "XBRL-OOS",
"start_character": 766,
"start_date_for_period": "2023-02-01",
"value": 8199999.999999999
},
{
"currency_/_unit": "USD",
"end_character": 787,
"end_date_for_period": "2022-04-30",
"label": "XBRL-OOS",
"start_character": 783,
"start_date_for_period": "2022-02-01",
"value": 73900000
},
{
"currency_/_unit": "USD",
"end_character": 998,
"end_date_for_period": "2023-04-30",
"label": "XBRL-OOS",
"start_character": 995,
"start_date_for_period": "2023-02-01",
"value": 8199999.999999999
},
{
"currency_/_unit": "USD",
"end_character": 1017,
"end_date_for_period": "2022-04-30",
"label": "XBRL-OOS",
"start_character": 1012,
"start_date_for_period": "2021-11-01",
"value": 151900000
}
] |
10-Q | 0001125345-23-000076 | 20230509160458 | 20230331 | MACROGENICS INC | In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte’s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $1.3 million and $0.3 million, respectively, for services performed under the Incyte Clinical Supply Agreement. | [
{
"currency_/_unit": "USD",
"end_character": 1086,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 1083,
"start_date_for_period": "2023-01-01",
"value": 1300000
},
{
"currency_/_unit": "USD",
"end_character": 1103,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 1100,
"start_date_for_period": "2022-01-01",
"value": 300000
}
] |
10-Q | 0001125345-23-000076 | 20230509160458 | 20230331 | MACROGENICS INC | Revenue related to the Lead Program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in 2021. During the three months ended March 31, 2023 the Company recognized no revenue under the 2021 Zai Lab Agreement, and the Company recognized revenue of $0.3 million during the three months ended March 31, 2022 under the 2021 Zai Lab Agreement. | [
{
"currency_/_unit": "USD",
"end_character": 766,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 763,
"start_date_for_period": "2022-01-01",
"value": 300000
}
] |
10-Q | 0001125345-23-000076 | 20230509160458 | 20230331 | MACROGENICS INC | During the three months ended March 31, 2023, the Company recognized $0.4 million in royalty revenue under these agreements based on the sales of TZIELD, and no revenue under these agreements during the three months ended March 31, 2022. As of March 31, 2023, Provention owed the Company $30.0 million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet. This receivable was due to be paid on June 1, 2023 and September 1, 2023 under the amended Asset Purchase Agreement. Provention was acquired by Sanofi in April 2023. Sanofi accelerated the payment schedule and paid the Company the balance due subsequent to March 31, 2023. | [
{
"currency_/_unit": "USD",
"end_character": 73,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 70,
"start_date_for_period": "2023-01-01",
"value": 400000
},
{
"currency_/_unit": "USD",
"end_character": 293,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 289,
"start_date_for_period": "2023-03-31",
"value": 30000000
}
] |
10-Q | 0001125345-23-000076 | 20230509160458 | 20230331 | MACROGENICS INC | In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab’s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023, the Company recognized no revenue for research and development activities performed under the I-Mab Clinical Supply Agreement. During the three months ended March 31, 2022, the Company recognized $0.9 million under the agreement. | [
{
"currency_/_unit": "USD",
"end_character": 165,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 163,
"start_date_for_period": "2023-01-01",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 1211,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 1208,
"start_date_for_period": "2022-01-01",
"value": 900000
}
] |
10-Q | 0001125345-23-000076 | 20230509160458 | 20230331 | MACROGENICS INC | The Company recognized revenue of $3.6 million under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended | [
{
"currency_/_unit": "USD",
"end_character": 38,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 35,
"start_date_for_period": "2023-01-01",
"value": 3600000
}
] |
10-Q | 0001846253-23-000070 | 20230511171105 | 20230331 | OmniAb, Inc. | For the three months ended March 31, 2023 and 2022, the Company’s revenue was $16.9 million and $9.6 million, respectively. For the three months ended March 31, 2023 and 2022, the Company’s net loss was $6.1 million and $6.3 million, respectively. The Company expects to continue to incur losses as it invests in research and development activities to improve its technology and platform, market and sell its technologies to existing and new partners, add operational, financial and management information systems and personnel to support its operations and incur additional costs associated with operating as a public company. The Company’s ability to continue its operations is dependent upon its ability to generate cash flows from operations and potentially obtain additional capital in the future. The Company believes its existing cash, cash equivalents and marketable securities and the cash it expects to generate from operations will provide it the flexibility needed to meet operating, investing, and financing needs and support operations through at least the next 12 months. | [
{
"currency_/_unit": "USD",
"end_character": 83,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 79,
"start_date_for_period": "2023-01-01",
"value": 16900000
},
{
"currency_/_unit": "USD",
"end_character": 100,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 97,
"start_date_for_period": "2022-01-01",
"value": 9600000
},
{
"currency_/_unit": "USD",
"end_character": 207,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 204,
"start_date_for_period": "2023-01-01",
"value": -6100000
},
{
"currency_/_unit": "USD",
"end_character": 224,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 221,
"start_date_for_period": "2022-01-01",
"value": -6300000
}
] |
10-Q | 0001601046-23-000054 | 20230531161000 | 20230430 | Keysight Technologies, Inc. | Beginning in fiscal year 2023, to align the presentation of revenue with the manner in which management reviews such information, the presentation of "products" and "services and other" revenue and the presentation of "costs and expenses" in the condensed consolidated statement of operations were reclassified to move revenue and costs and expenses primarily related to bundled licenses and technical support services from products to "services and other." This resulted in reclassification of $20 million and $40 million, respectively, from "products" revenue to "services and other" revenue for the three and six months ended April 30, 2022, and $2 million and $5 million, respectively, from "cost of products" to "cost of services and other" for the three and six months ended April 30, 2022 to conform to the current presentation. This change had no impact on reported total revenue, income from operations and net income in our condensed consolidated statement of operations. | [
{
"currency_/_unit": "USD",
"end_character": 27,
"end_date_for_period": "2022-04-30",
"label": "revenues",
"start_character": 25,
"start_date_for_period": "2022-02-01",
"value": 20000000
},
{
"currency_/_unit": "USD",
"end_character": 514,
"end_date_for_period": "2022-04-30",
"label": "revenues",
"start_character": 512,
"start_date_for_period": "2021-11-01",
"value": 40000000
},
{
"currency_/_unit": "USD",
"end_character": 640,
"end_date_for_period": "2022-04-30",
"label": "XBRL-OOS",
"start_character": 639,
"start_date_for_period": "2022-02-01",
"value": 2000000
},
{
"currency_/_unit": "USD",
"end_character": 666,
"end_date_for_period": "2022-04-30",
"label": "XBRL-OOS",
"start_character": 665,
"start_date_for_period": "2021-11-01",
"value": 5000000
}
] |
10-Q | 0000916540-23-000018 | 20230509165007 | 20230401 | DARLING INGREDIENTS INC. | The amount of net sales and net loss from the Valley Acquisition included in the Company's consolidated statement of operations for the three months ended April 1, 2023 were $226.4 million and $(0.5) million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 180,
"end_date_for_period": "2023-04-01",
"label": "XBRL-OOS",
"start_character": 175,
"start_date_for_period": "2023-01-01",
"value": 226400000
},
{
"currency_/_unit": "USD",
"end_character": 198,
"end_date_for_period": "2023-04-01",
"label": "earnings",
"start_character": 195,
"start_date_for_period": "2023-01-01",
"value": -500000
}
] |
10-Q | 0001169445-23-000008 | 20230510160502 | 20230331 | COMPUTER PROGRAMS & SYSTEMS INC | During 2021, 2022, and 2023, performance share awards were granted to certain executive officers and key employees of the Company that will result in the issuance of common stock if the predefined performance criteria are met. The awards provide for an aggregate target of 279,712 shares, of which none have been included in the calculation of diluted EPS for the three months ended March 31, 2023 because the related threshold award performance levels have not been achieved as of March 31, 2023. See Note 10 - Stock-Based Compensation and Equity for more information. | [
{
"currency_/_unit": "shares",
"end_character": 282,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 275,
"start_date_for_period": "2023-01-01",
"value": 279712
},
{
"currency_/_unit": "shares",
"end_character": 304,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 300,
"start_date_for_period": "2023-01-01",
"value": 0
}
] |
10-Q | 0001493152-23-016926 | 20230515080048 | 20230331 | WIRELESS TELECOM GROUP INC | The
Company recorded a tax benefit of $162,000 in the three months ended March 31, 2023 based on the estimated effective annual tax rate.
In accordance with Accounting Standards Update (“ASU”) 2019-12 the Company recorded a tax provision of approximately $4.9
million related to income from discontinued operations and a tax benefit of approximately $856,000 related to loss from continuing operations
for the three months ended March 31, 2022. | [
{
"currency_/_unit": "USD",
"end_character": 259,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 256,
"start_date_for_period": "2023-01-01",
"value": 4900000
},
{
"currency_/_unit": "USD",
"end_character": 358,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 351,
"start_date_for_period": "2022-01-01",
"value": 856000000
}
] |
10-Q | 0001437749-23-013612 | 20230510161909 | 20230331 | ROCKY BRANDS, INC. | Due to a loss for the three months ended March 31, 2023, zero dilutive stock options are included for the period because the effect would be antidilutive. | [
{
"currency_/_unit": "shares",
"end_character": 62,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 58,
"start_date_for_period": "2023-01-01",
"value": 0
}
] |
10-Q | 0001628280-23-014920 | 20230502171151 | 20230331 | Aquestive Therapeutics, Inc. | On September 24, 2017, the Company entered into an agreement with Indivior, or the Indivior Supplemental Agreement. Pursuant to the Indivior Supplemental Agreement, the Company conveyed to Indivior all existing and future rights in the settlement of various ongoing patent enforcement legal actions and disputes related to the Suboxone product. The Company also conveyed to Indivior the right to sublicense manufacturing and marketing capabilities to enable an Indivior licensed generic buprenorphine product to be produced and sold by parties unrelated to Indivior or Aquestive. Under the Indivior Supplemental Agreement, the Company was entitled to receive certain payments from Indivior commencing on the date of the Indivior Supplemental Agreement through January 1, 2023. Once paid, all payments made under the Indivior Supplemental Agreement are non-refundable. Through February 20, 2019, the at-risk launch date of the competing generic products of Dr. Reddy’s Labs and Alvogen, the Company received an aggregate of $40,750 from Indivior under the Indivior Supplemental Agreement. Further payments under the Indivior Supplemental Agreement were suspended until adjudication of related patent infringement litigation is finalized. As a result of the settlement and dismissal of all claims under the lawsuit with Dr. Reddy’s Labs on June 28, 2022, no further payments are due to the Company under the Indivior Supplemental Agreement. See Note 19, | [
{
"currency_/_unit": "USD",
"end_character": 1030,
"end_date_for_period": "2019-02-20",
"label": "revenues",
"start_character": 1024,
"start_date_for_period": "2017-09-24",
"value": 40750000
}
] |
10-Q | 0001628280-23-014920 | 20230502171151 | 20230331 | Aquestive Therapeutics, Inc. | In consideration of the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $22,000 to date. In addition to the upfront payment of $5,000, the Company has also earned an aggregate of $17,000 in connection with specified regulatory and development milestones in the United States and Europe (the “Initial Milestone Payments”), all of which have been received to date. With the Monetization Agreement entered into on November 3, 2020 relating to KYNMOBI as described in the paragraph below, we are no longer entitled to receive any payments under the Sunovion License Agreement. | [
{
"currency_/_unit": "USD",
"end_character": 145,
"end_date_for_period": "2016-04-01",
"label": "revenues",
"start_character": 139,
"start_date_for_period": "2016-04-01",
"value": 22000000
},
{
"currency_/_unit": "USD",
"end_character": 199,
"end_date_for_period": "2016-04-01",
"label": "revenues",
"start_character": 194,
"start_date_for_period": "2016-04-01",
"value": 5000000
},
{
"currency_/_unit": "USD",
"end_character": 252,
"end_date_for_period": "2016-04-01",
"label": "revenues",
"start_character": 246,
"start_date_for_period": "2016-04-01",
"value": 17000000
}
] |
10-Q | 0001065059-23-000015 | 20230509170409 | 20230331 | CENTRUS ENERGY CORP | In the three months ended March 31, 2023, two customers in the LEU segment individually represented $41.6 million and $8.4 million of revenue and one customer in the Technical Solutions segment individually represented $8.0 million of revenue. | [
{
"currency_/_unit": "USD",
"end_character": 105,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 101,
"start_date_for_period": "2023-01-01",
"value": 41600000
},
{
"currency_/_unit": "USD",
"end_character": 122,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 119,
"start_date_for_period": "2023-01-01",
"value": 8400000
},
{
"currency_/_unit": "USD",
"end_character": 223,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 220,
"start_date_for_period": "2023-01-01",
"value": 8000000
}
] |
10-Q | 0001813756-23-000040 | 20230510162719 | 20230331 | WeWork Inc. | The Company has incurred net losses of $0.3 billion, $2.3 billion, $4.6 billion, and $3.8 billion, for the three months ended March 31, 2023 and the years ended December 31, 2022, 2021, and 2020, respectively, and negative cash flow from operating activities of $0.3 billion, $0.7 billion, $1.9 billion, and $0.9 billion, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 43,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 40,
"start_date_for_period": "2023-01-01",
"value": -300000000
},
{
"currency_/_unit": "USD",
"end_character": 57,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 54,
"start_date_for_period": "2022-01-01",
"value": -2300000000
},
{
"currency_/_unit": "USD",
"end_character": 71,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 68,
"start_date_for_period": "2021-01-01",
"value": -4600000000
},
{
"currency_/_unit": "USD",
"end_character": 89,
"end_date_for_period": "2020-12-31",
"label": "earnings",
"start_character": 86,
"start_date_for_period": "2020-01-01",
"value": -3800000000
},
{
"currency_/_unit": "USD",
"end_character": 266,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 263,
"start_date_for_period": "2023-01-01",
"value": -300000000
},
{
"currency_/_unit": "USD",
"end_character": 280,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 277,
"start_date_for_period": "2022-01-01",
"value": -700000000
},
{
"currency_/_unit": "USD",
"end_character": 294,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 291,
"start_date_for_period": "2021-01-01",
"value": -1900000000
},
{
"currency_/_unit": "USD",
"end_character": 312,
"end_date_for_period": "2020-12-31",
"label": "XBRL-OOS",
"start_character": 309,
"start_date_for_period": "2020-01-01",
"value": -900000000
}
] |
10-Q | 0000732712-23-000029 | 20230427105248 | 20230331 | VERIZON COMMUNICATIONS INC | There were a total of approximately 3.6 million outstanding dilutive securities, primarily consisting of performance stock units and restricted stock units, included in the computation of diluted earnings per common share for the three months ended March 31, 2023. There were a total of approximately 1.5 million outstanding dilutive securities, primarily consisting of restricted stock units, included in the computation of diluted earnings per common share for the three months ended March 31, 2022. | [
{
"currency_/_unit": "shares",
"end_character": 39,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 36,
"start_date_for_period": "2023-01-01",
"value": 3600000
},
{
"currency_/_unit": "shares",
"end_character": 304,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 301,
"start_date_for_period": "2022-01-01",
"value": 1500000
}
] |
10-Q | 0000732712-23-000029 | 20230427105248 | 20230331 | VERIZON COMMUNICATIONS INC | Service and other revenues and Wireless equipment revenues included in our Business segment were approximately $6.6 billion and $882 million, respectively, for the three months ended March 31, 2023, and were approximately $6.7 billion and $962 million, respectively, for the three months ended March 31, 2022. | [
{
"currency_/_unit": "USD",
"end_character": 115,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 112,
"start_date_for_period": "2023-01-01",
"value": 6600000000
},
{
"currency_/_unit": "USD",
"end_character": 132,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 129,
"start_date_for_period": "2023-01-01",
"value": 882000000
},
{
"currency_/_unit": "USD",
"end_character": 226,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 223,
"start_date_for_period": "2022-01-01",
"value": 6700000000
},
{
"currency_/_unit": "USD",
"end_character": 243,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 240,
"start_date_for_period": "2022-01-01",
"value": 962000000
}
] |
10-Q | 0001403256-23-000084 | 20230505163257 | 20230331 | Sculptor Capital Management, Inc. | For the three months ended March 31, 2023 and 2022 the Company included 203,677 and 186,944 RSUs respectively, that have vested but have not been settled in Class A Shares in the weighted-average Class A Shares outstanding used to calculate basic and diluted earnings per Class A Share. | [
{
"currency_/_unit": "shares",
"end_character": 79,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 72,
"start_date_for_period": "2023-01-01",
"value": 203677
},
{
"currency_/_unit": "shares",
"end_character": 91,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 84,
"start_date_for_period": "2022-01-01",
"value": 186944
}
] |
10-Q | 0001493152-23-018956 | 20230524172642 | 20220930 | Lottery.com Inc. | The Company has experienced recurring net losses and negative cash
flows from operations and has an accumulated deficit of approximately $204 million and a working capital of approximately $5.4 million
at September 30, 2022. For the three and nine months ended September 30, 2022, the Company sustained loss from operations of $6.1 million
and $52.3 million, respectively. The Company had loss from operations of $5.8 million and $10.5 million for the three and nine months
ended September 30, 2021, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 141,
"end_date_for_period": "2022-09-30",
"label": "XBRL-OOS",
"start_character": 138,
"start_date_for_period": "2022-09-30",
"value": -204000000
},
{
"currency_/_unit": "USD",
"end_character": 193,
"end_date_for_period": "2022-09-30",
"label": "XBRL-OOS",
"start_character": 190,
"start_date_for_period": "2022-09-30",
"value": 5400000
},
{
"currency_/_unit": "USD",
"end_character": 331,
"end_date_for_period": "2022-09-30",
"label": "ebit",
"start_character": 328,
"start_date_for_period": "2022-07-01",
"value": -6100000
},
{
"currency_/_unit": "USD",
"end_character": 349,
"end_date_for_period": "2022-09-30",
"label": "ebit",
"start_character": 345,
"start_date_for_period": "2022-01-01",
"value": -52300000
},
{
"currency_/_unit": "USD",
"end_character": 417,
"end_date_for_period": "2021-09-30",
"label": "ebit",
"start_character": 414,
"start_date_for_period": "2021-07-01",
"value": -5800000
},
{
"currency_/_unit": "USD",
"end_character": 435,
"end_date_for_period": "2021-09-30",
"label": "ebit",
"start_character": 431,
"start_date_for_period": "2021-01-01",
"value": -10500000
}
] |
10-Q | 0000894081-23-000185 | 20230510092455 | 20230331 | Air Transport Services Group, Inc. | Basic weighted average shares outstanding for purposes of basic earnings per share are less than the shares outstanding due to 226,149 shares and 392,039 shares of restricted stock for 2023 and 2022, respectively, which are accounted for as part of diluted weighted average shares outstanding in diluted earnings per share. | [
{
"currency_/_unit": "shares",
"end_character": 134,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 127,
"start_date_for_period": "2023-01-01",
"value": 226149
},
{
"currency_/_unit": "shares",
"end_character": 153,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 146,
"start_date_for_period": "2022-01-01",
"value": 392039
}
] |
10-Q | 0001495240-23-000012 | 20230508160559 | 20230331 | GLADSTONE LAND Corp | The weighted-average number of OP Units held by non-controlling OP Unitholders was 0 and 204,778 for the three months ended March 31, 2023 and 2022, | [
{
"currency_/_unit": "shares",
"end_character": 84,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 83,
"start_date_for_period": "2023-01-01",
"value": 0
},
{
"currency_/_unit": "shares",
"end_character": 96,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 89,
"start_date_for_period": "2022-01-01",
"value": 204778
}
] |
10-Q | 0001401708-23-000116 | 20230503170047 | 20230331 | NanoString Technologies Inc | Total revenue in the United States was $21.3 million and $20.4 million, for the three month periods ended March 31, 2023 and 2022, respectively. The Company’s assets are primarily located in the United States and therefore are not allocated to any specific geographic region. | [
{
"currency_/_unit": "USD",
"end_character": 44,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 40,
"start_date_for_period": "2023-01-01",
"value": 21300000
},
{
"currency_/_unit": "USD",
"end_character": 62,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 58,
"start_date_for_period": "2022-01-01",
"value": 20400000
}
] |
10-Q | 0000277509-23-000033 | 20230502134028 | 20230331 | FEDERAL SIGNAL CORP /DE/ | In the period between the January 3, 2023 closing date and March 31, 2023, Blasters generated $5.9 million of net sales and $0.6 million of operating income. The acquisition was not, and would not have been, material to the Company’s net sales or results of operations for the three months ended March 31, 2022. Accordingly, the Company’s consolidated results do not differ materially from historical performance as a result of the acquisition, and therefore, unaudited pro-forma results are not presented. | [
{
"currency_/_unit": "USD",
"end_character": 98,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 95,
"start_date_for_period": "2023-01-01",
"value": 5900000
},
{
"currency_/_unit": "USD",
"end_character": 128,
"end_date_for_period": "2023-03-31",
"label": "ebit",
"start_character": 125,
"start_date_for_period": "2023-01-01",
"value": 600000
}
] |
10-Q | 0001039684-23-000037 | 20230503161753 | 20230331 | ONEOK INC /NEW/ | (a) - Our Natural Gas Liquids segment has regulated and nonregulated operations. Our Natural Gas Liquids segment’s regulated operations had revenues of $638 million, of which $577 million related to revenues within the segment, cost of sales and fuel of $184 million and operating costs of $87 million. | [
{
"currency_/_unit": "USD",
"end_character": 157,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 154,
"start_date_for_period": "2023-01-01",
"value": 638000000
},
{
"currency_/_unit": "USD",
"end_character": 180,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 177,
"start_date_for_period": "2023-01-01",
"value": 577000000
},
{
"currency_/_unit": "USD",
"end_character": 259,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 256,
"start_date_for_period": "2023-01-01",
"value": 184000000
},
{
"currency_/_unit": "USD",
"end_character": 294,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 292,
"start_date_for_period": "2023-01-01",
"value": 87000000
}
] |
10-Q | 0001039684-23-000037 | 20230503161753 | 20230331 | ONEOK INC /NEW/ | (c) - Intersegment revenues are primarily commodity sales, which are based on the contracted selling price that is generally index-based and settled monthly, and for our Natural Gas Gathering and Processing segment totaled $631 million. Intersegment revenues for our Natural Gas Liquids and Natural Gas Pipelines segments were not material. | [
{
"currency_/_unit": "USD",
"end_character": 227,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 224,
"start_date_for_period": "2023-01-01",
"value": 631000000
}
] |
10-Q | 0001039684-23-000037 | 20230503161753 | 20230331 | ONEOK INC /NEW/ | (a) - Our Natural Gas Liquids segment has regulated and nonregulated operations. Our Natural Gas Liquids segment’s regulated operations had revenues of $604 million, of which $547 million related to revenues within the segment, cost of sales and fuel of $146 million and operating costs of $75 million. | [
{
"currency_/_unit": "USD",
"end_character": 157,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 154,
"start_date_for_period": "2022-01-01",
"value": 604000000
},
{
"currency_/_unit": "USD",
"end_character": 180,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 177,
"start_date_for_period": "2022-01-01",
"value": 547000000
},
{
"currency_/_unit": "USD",
"end_character": 259,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 256,
"start_date_for_period": "2022-01-01",
"value": 146000000
},
{
"currency_/_unit": "USD",
"end_character": 294,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 292,
"start_date_for_period": "2022-01-01",
"value": 75000000
}
] |
10-Q | 0001039684-23-000037 | 20230503161753 | 20230331 | ONEOK INC /NEW/ | (c) - Intersegment revenues are primarily commodity sales, which are based on the contracted selling price that is generally index-based and settled monthly, and for our Natural Gas Gathering and Processing segment totaled $1.0 billion. Intersegment revenues for our Natural Gas Liquids and Natural Gas Pipelines segments were not material. | [
{
"currency_/_unit": "USD",
"end_character": 227,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 224,
"start_date_for_period": "2022-01-01",
"value": 1000000000
}
] |
10-Q | 0001039684-23-000037 | 20230503161753 | 20230331 | ONEOK INC /NEW/ | (a) - Noncustomer revenue for the three months ended March 31, 2022, totaled $(175) million related primarily to losses from derivatives on commodity contracts. | [
{
"currency_/_unit": "USD",
"end_character": 82,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 79,
"start_date_for_period": "2022-01-01",
"value": -175000000
}
] |
10-Q | 0001628280-23-024026 | 20230630160603 | 20230531 | LENNAR CORP /NEW/ | Revenues for Multifamily for the six months ended May 31, 2022, included $147.8 million of land sales to unconsolidated entities. | [
{
"currency_/_unit": "USD",
"end_character": 79,
"end_date_for_period": "2022-05-31",
"label": "revenues",
"start_character": 74,
"start_date_for_period": "2021-12-01",
"value": 147800000
}
] |
10-Q | 0001747079-23-000057 | 20230509162102 | 20230331 | Bally's Corp | The Company leases its hotel rooms to patrons and records the corresponding lessor revenue in “Non-gaming revenue” within our condensed consolidated statements of operations. For the three months ended March 31, 2023 and 2022, the Company recognized $47.3 million and $26.9 million of lessor revenues related to the rental of hotel rooms, respectively. Hotel leasing arrangements vary in duration, but are short-term in nature. The cost and accumulated depreciation of property and equipment associated with hotel rooms is included in “Property and equipment, net” within our condensed consolidated balance sheets. | [
{
"currency_/_unit": "USD",
"end_character": 255,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 251,
"start_date_for_period": "2023-01-01",
"value": 47300000
},
{
"currency_/_unit": "USD",
"end_character": 273,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 269,
"start_date_for_period": "2022-01-01",
"value": 26900000
}
] |
10-Q | 0001493152-23-016842 | 20230515061420 | 20230331 | Prairie Operating Co. | Historically,
we have relied upon cash from financing activities to fund substantially all of the cash requirements of our activities and have
incurred significant losses and experienced negative cash flow. The Company had net losses from continuing operations of $971,366 | [
{
"currency_/_unit": "USD",
"end_character": 272,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 265,
"start_date_for_period": "2023-01-01",
"value": -971366
}
] |
10-Q | 0001493152-23-017294 | 20230515160559 | 20230331 | INVO Bioscience, Inc. | The
Company determined the Georgia JV is a VIE, and that the Company is its primary beneficiary because the Company has an obligation to
absorb losses that are potentially significant and the Company controls the majority of the activities that impact the Georgia JV’s
economic performance, specifically control of the INVOcell and lab services quality management. As a result, the Company consolidated
the Georgia JV’s results with its own. As of March 31, 2023, the Company invested $0.9 million in the Georgia JV in the form of
capital contributions as well as $0.5 million in the form of a note. For the three months ended March 31, 2023 and 2022, the Georgia
JV recorded net losses of $32 thousand and $0.2 million respectively. Noncontrolling interest in the Georgia JV was $0. | [
{
"currency_/_unit": "USD",
"end_character": 489,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 486,
"start_date_for_period": "2023-03-31",
"value": 900000
},
{
"currency_/_unit": "USD",
"end_character": 568,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 565,
"start_date_for_period": "2023-03-31",
"value": 500000
},
{
"currency_/_unit": "USD",
"end_character": 693,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 691,
"start_date_for_period": "2023-01-01",
"value": 32000
},
{
"currency_/_unit": "USD",
"end_character": 711,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 708,
"start_date_for_period": "2022-01-01",
"value": 200000
}
] |
10-Q | 0001628280-23-015766 | 20230504162039 | 20230331 | NGM BIOPHARMACEUTICALS INC | Since inception, the Company has incurred net losses and negative cash flow from operations. During the three months ended March 31, 2023 and 2022, net losses were $47.6 million and $32.5 million, respectively. As of March 31, 2023, the Company had an accumulated deficit of $629.3 million. The Company expects its accumulated deficit will continue to increase over time and does not expect to experience positive cash flows from operations in the near future. | [
{
"currency_/_unit": "USD",
"end_character": 169,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 165,
"start_date_for_period": "2023-01-01",
"value": -47600000
},
{
"currency_/_unit": "USD",
"end_character": 187,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 183,
"start_date_for_period": "2022-01-01",
"value": -32500000
},
{
"currency_/_unit": "USD",
"end_character": 281,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 276,
"start_date_for_period": "2023-03-31",
"value": -629300000
}
] |
10-Q | 0001759509-23-000063 | 20230508160930 | 20230331 | Lyft, Inc. | For the three months ended March 31, 2023, in relation to the driver, rider and Light Vehicle riders incentive programs, the Company recorded $303.7 million as a reduction to revenue and $23.3 million as sales and marketing expense. For the three months ended March 31, 2022, in relation to the driver, rider and Light Vehicle riders incentive programs, the Company recorded $349.9 million as a reduction to revenue and $24.9 million as sales and marketing expense. | [
{
"currency_/_unit": "USD",
"end_character": 148,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 143,
"start_date_for_period": "2023-01-01",
"value": -303700000
},
{
"currency_/_unit": "USD",
"end_character": 192,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 188,
"start_date_for_period": "2023-01-01",
"value": 23300000
},
{
"currency_/_unit": "USD",
"end_character": 381,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 376,
"start_date_for_period": "2022-01-01",
"value": -349900000
},
{
"currency_/_unit": "USD",
"end_character": 425,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 421,
"start_date_for_period": "2022-01-01",
"value": 24900000
}
] |
10-Q | 0000025232-23-000035 | 20230427161815 | 20230331 | COUSINS PROPERTIES INC | For the three months ended March 31, 2022, the Company recognized fee and other revenue of $3.7 million. The $3.7 million fee and other revenue includes $814,000 of income related to the Company's consulting and development contracts with Norfolk Southern Railway Company, as discussed in note 3 of | [
{
"currency_/_unit": "USD",
"end_character": 95,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 92,
"start_date_for_period": "2022-01-01",
"value": 3700000
},
{
"currency_/_unit": "USD",
"end_character": 113,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 110,
"start_date_for_period": "2022-01-01",
"value": 3700000
},
{
"currency_/_unit": "USD",
"end_character": 161,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 154,
"start_date_for_period": "2022-01-01",
"value": 814000
}
] |
10-Q | 0001579877-23-000049 | 20230508160908 | 20230331 | OUTFRONT Media Inc. | We recorded rental income of $298.4 million for the three months ended March 31, 2023, and $288.3 million for the three months ended March 31, 2022, in | [
{
"currency_/_unit": "USD",
"end_character": 35,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 30,
"start_date_for_period": "2023-01-01",
"value": 298400000
},
{
"currency_/_unit": "USD",
"end_character": 97,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 92,
"start_date_for_period": "2022-01-01",
"value": 288300000
}
] |
10-Q | 0001579877-23-000049 | 20230508160908 | 20230331 | OUTFRONT Media Inc. | Rental income was $298.4 million in the three months ended March 31, 2023, and $288.3 million in the three months ended March 31, 2022, and is recorded in | [
{
"currency_/_unit": "USD",
"end_character": 24,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 19,
"start_date_for_period": "2023-01-01",
"value": 298400000
},
{
"currency_/_unit": "USD",
"end_character": 85,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 80,
"start_date_for_period": "2022-01-01",
"value": 288300000
}
] |
10-Q | 0001493152-23-017462 | 20230515164445 | 20230331 | PIONEER POWER SOLUTIONS, INC. | In
connection with the preparation of our consolidated interim financial statements for the quarter ended September 30, 2022, we completed
an analysis of one of our customer contracts under ASC 606 and, as a result, we determined that the performance obligations are satisfied
over time. See “Note 3 – Revenues in Notes to Consolidated Financial Statements” in Part I of this Quarterly Report
on Form 10-Q. As a result of the analysis, we identified additional revenues to be recognized of $326 related to the three months ended
March 31, 2022 along with the additional related cost of revenues of $278. | [
{
"currency_/_unit": "USD",
"end_character": 494,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 491,
"start_date_for_period": "2023-01-01",
"value": 326000
},
{
"currency_/_unit": "USD",
"end_character": 602,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 599,
"start_date_for_period": "2023-01-01",
"value": 278000
}
] |
10-Q | 0000016732-23-000076 | 20230607073944 | 20230430 | CAMPBELL SOUP CO | The business had net sales of $16 million and $46 million for the three- and nine-month periods ended April 30, 2023, and $17 million and $49 million for the three- and nine-month periods ended May 1, 2022, respectively. The business had net sales of $66 million for the year ended July 31, 2022. Earnings were not material in the periods. The results of the business through the date of sale are reflected within the Snacks reportable segment. | [
{
"currency_/_unit": "USD",
"end_character": 33,
"end_date_for_period": "2023-04-30",
"label": "revenues",
"start_character": 31,
"start_date_for_period": "2023-01-30",
"value": 16000000
},
{
"currency_/_unit": "USD",
"end_character": 49,
"end_date_for_period": "2023-04-30",
"label": "revenues",
"start_character": 47,
"start_date_for_period": "2022-08-01",
"value": 46000000
},
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2022-05-01",
"label": "revenues",
"start_character": 123,
"start_date_for_period": "2022-01-31",
"value": 17000000
},
{
"currency_/_unit": "USD",
"end_character": 141,
"end_date_for_period": "2022-05-01",
"label": "revenues",
"start_character": 139,
"start_date_for_period": "2021-08-02",
"value": 49000000
},
{
"currency_/_unit": "USD",
"end_character": 254,
"end_date_for_period": "2022-07-31",
"label": "revenues",
"start_character": 252,
"start_date_for_period": "2021-08-02",
"value": 66000000
}
] |
10-Q | 0001423902-23-000041 | 20230503161759 | 20230331 | Western Midstream Partners, LP | Total revenues and other includes related-party amounts of $448.8 million and $428.7 million for the three months ended March 31, 2023 and 2022, respectively. See | [
{
"currency_/_unit": "USD",
"end_character": 65,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 60,
"start_date_for_period": "2023-01-01",
"value": 448800000
},
{
"currency_/_unit": "USD",
"end_character": 84,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 79,
"start_date_for_period": "2022-01-01",
"value": 428700000
}
] |
10-Q | 0001423902-23-000041 | 20230503161759 | 20230331 | Western Midstream Partners, LP | Total revenues and other includes related-party amounts of $448.8 million and $428.7 million for the three months ended March 31, 2023 and 2022, respectively. See | [
{
"currency_/_unit": "USD",
"end_character": 65,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 60,
"start_date_for_period": "2023-01-01",
"value": 448800000
},
{
"currency_/_unit": "USD",
"end_character": 84,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 79,
"start_date_for_period": "2022-01-01",
"value": 428700000
}
] |
10-Q | 0001628280-23-014741 | 20230502063545 | 20230331 | ESAB Corp | During the three months ended March 31, 2023, Income from continuing operations before income taxes was $71.2 million | [
{
"currency_/_unit": "USD",
"end_character": 109,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 105,
"start_date_for_period": "2023-01-01",
"value": 71200000
}
] |
10-Q | 0001476150-23-000007 | 20230503160114 | 20230331 | Terreno Realty Corp | The Company recorded revenues and net loss for the three months ended March 31, 2023 of approximately $0.3 million and $0.2 million, respectively, related to the 2023 acquisitions. | [
{
"currency_/_unit": "USD",
"end_character": 106,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 103,
"start_date_for_period": "2023-01-01",
"value": 300000
},
{
"currency_/_unit": "USD",
"end_character": 123,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 120,
"start_date_for_period": "2023-01-01",
"value": -200000
}
] |
10-Q | 0001476150-23-000007 | 20230503160114 | 20230331 | Terreno Realty Corp | The Company recorded revenues and net income for the three months ended March 31, 2022 of approximately $0.1 million and $0.1 million, respectively, related to the 2022 acquisitions. | [
{
"currency_/_unit": "USD",
"end_character": 108,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 105,
"start_date_for_period": "2022-01-01",
"value": 100000
},
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 122,
"start_date_for_period": "2022-01-01",
"value": 100000
}
] |
10-Q | 0001476150-23-000007 | 20230503160114 | 20230331 | Terreno Realty Corp | In accordance with the Company’s policies of determining whether instruments granted in share-based payment transactions are participating securities and accounting for earnings per share, the net income (loss) per common share is adjusted for earnings distributed through declared dividends (if any) and allocated to all participating securities (weighted average common shares outstanding and unvested restricted shares outstanding) under the two-class method. Under this method, allocations were made to 373,985 and 303,666 of weighted average unvested restricted shares outstanding for the three months ended March 31, 2023 and 2022, respectively. | [
{
"currency_/_unit": "shares",
"end_character": 514,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 507,
"start_date_for_period": "2023-01-01",
"value": 373985
},
{
"currency_/_unit": "shares",
"end_character": 526,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 519,
"start_date_for_period": "2022-01-01",
"value": 303666
}
] |
10-Q | 0001628280-23-016013 | 20230505092340 | 20230331 | Ovid Therapeutics Inc. | The Company recorded a net loss of $13.4 million during the three months ended March 31, 2023, and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company’s existing cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company’s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company’s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently. | [
{
"currency_/_unit": "USD",
"end_character": 40,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 36,
"start_date_for_period": "2023-01-01",
"value": -13400000
}
] |
10-Q | 0001133421-23-000027 | 20230427064048 | 20230331 | NORTHROP GRUMMAN CORP /DE/ | EAC adjustments on a single performance obligation can have a significant effect on the company’s financial statements. When such adjustments occur, we generally disclose the nature, underlying conditions and financial impact of the adjustments. During the three months ended March 31, 2022, we recorded a $67 million favorable | [
{
"currency_/_unit": "USD",
"end_character": 309,
"end_date_for_period": "2022-03-31",
"label": "ebit",
"start_character": 307,
"start_date_for_period": "2022-01-01",
"value": 67000000
}
] |
10-Q | 0001133421-23-000027 | 20230427064048 | 20230331 | NORTHROP GRUMMAN CORP /DE/ | Diluted earnings per share include the dilutive effect of awards granted to employees under stock-based compensation plans. The dilutive effect of these securities totaled 0.6 million shares for each of the three month periods ended March 31, 2023 and 2022. | [
{
"currency_/_unit": "shares",
"end_character": 175,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 172,
"start_date_for_period": "2022-01-01",
"value": 600000
}
] |
10-Q | 0000350894-23-000055 | 20230424154743 | 20230331 | SEI INVESTMENTS CO | (1) Professional services fees of the Private Banks segment includes one-time early termination fees of $88,000 related to a contractual agreement with a significant client of the Company. In accordance with Accounting Standards Codification 606, the entire amount of the fees received were recorded during the three months ended March 31, 2022 as there were no future performance obligations of the Company related to the agreement upon termination. | [
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 105,
"start_date_for_period": "2022-01-01",
"value": 88000000
}
] |
10-Q | 0001628280-23-016486 | 20230508171108 | 20230331 | SANGAMO THERAPEUTICS, INC | Although the Company reported net income of $21.1 million for the three months ended March 31, 2023 primarily due to the termination of a collaboration agreement, the Company has a history of recurring net losses, including $192.3 million and $178.3 million for the years ended December 31, 2022 and 2021, respectively; and | [
{
"currency_/_unit": "USD",
"end_character": 49,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 45,
"start_date_for_period": "2023-01-01",
"value": 21100000
},
{
"currency_/_unit": "USD",
"end_character": 230,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 225,
"start_date_for_period": "2022-01-01",
"value": -192300000
},
{
"currency_/_unit": "USD",
"end_character": 249,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 244,
"start_date_for_period": "2021-01-01",
"value": -178300000
}
] |
10-Q | 0000010048-23-000011 | 20230515164232 | 20230331 | BARNWELL INDUSTRIES INC | The following table presents certain financial information related to Barnwell’s reporting segments. All revenues reported are from external customers with no intersegment sales or transfers. | [
{
"currency_/_unit": "USD",
"end_character": 158,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 156,
"start_date_for_period": "2022-10-01",
"value": 0
}
] |
10-Q | 0001866550-23-000037 | 20230509070627 | 20230331 | Thoughtworks Holding, Inc. | In the fourth quarter of 2022, the Company changed its stock-based compensation policy for recognizing expense for graded vesting awards with only service conditions from the accelerated attribution method to the straight-line attribution method. The Company believes the straight-line attribution method for stock-based compensation expense for awards solely subject to time-based vesting conditions is the preferable accounting policy in accordance with ASC 250, Accounting Changes and Error Corrections, because it more accurately reflects how the award is earned over the service period and is the predominant method used in its industry. The Company applied the change retrospectively adjusting all periods presented resulting in a decrease to net loss of $16.3 million and a decrease to basic and diluted loss per share of $0.06 for the first quarter of 2022. | [
{
"currency_/_unit": "USD",
"end_character": 766,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 762,
"start_date_for_period": "2022-01-01",
"value": -16300000
}
] |
10-Q | 0001069258-23-000027 | 20230503162059 | 20230326 | KRATOS DEFENSE & SECURITY SOLUTIONS, INC. | Revenue from the U.S. Government, which includes foreign military sales contracted through the U.S. Government, includes revenue from contracts for which the Company is the prime contractor as well as those for which the Company is a subcontractor and the ultimate customer is the U.S. Government. The KGS and US segments have substantial revenue from the U.S. Government. Sales to the U.S. Government amounted to approximately $160.3 million and $139.6 million, or 69% and 71% of total Kratos revenue, for the three months ended March 26, 2023 and March 27, 2022, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 434,
"end_date_for_period": "2023-03-26",
"label": "revenues",
"start_character": 429,
"start_date_for_period": "2022-12-26",
"value": 160300000
},
{
"currency_/_unit": "USD",
"end_character": 453,
"end_date_for_period": "2022-03-27",
"label": "revenues",
"start_character": 448,
"start_date_for_period": "2021-12-27",
"value": 139600000
},
{
"currency_/_unit": "pure",
"end_character": 468,
"end_date_for_period": "2023-03-26",
"label": "XBRL-OOS",
"start_character": 466,
"start_date_for_period": "2022-12-26",
"value": 0.6900000000000001
},
{
"currency_/_unit": "pure",
"end_character": 476,
"end_date_for_period": "2022-03-27",
"label": "XBRL-OOS",
"start_character": 474,
"start_date_for_period": "2021-12-27",
"value": 0.71
}
] |
10-Q | 0001404912-23-000015 | 20230510163229 | 20230331 | KKR & Co. Inc. | The cumulative impact of the retrospective application of the LDTI adoption increased net income attributable to shareholders by $319.5 million and $65.9 million for each of the periods ended December 31, 2022 and 2021, respectively ($385.4 million cumulatively), and increased other comprehensive income by $589.6 million and $10.3 million for each of the periods ended December 31, 2022 and 2021, respectively ($599.9 million cumulatively). These increases were primarily as a result of an increase in discount rates and Global Atlantic’s instrument-specific credit risk during each of the respective periods. | [
{
"currency_/_unit": "USD",
"end_character": 135,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 130,
"start_date_for_period": "2022-01-01",
"value": 319500000
},
{
"currency_/_unit": "USD",
"end_character": 153,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 149,
"start_date_for_period": "2021-01-01",
"value": 65900000.00000001
},
{
"currency_/_unit": "USD",
"end_character": 240,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 235,
"start_date_for_period": "2021-01-01",
"value": 385400000
},
{
"currency_/_unit": "USD",
"end_character": 314,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 309,
"start_date_for_period": "2022-01-01",
"value": 589600000
},
{
"currency_/_unit": "USD",
"end_character": 332,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 328,
"start_date_for_period": "2021-01-01",
"value": 10300000
},
{
"currency_/_unit": "USD",
"end_character": 419,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 414,
"start_date_for_period": "2021-01-01",
"value": 599900000
}
] |
10-Q | 0001493152-23-014050 | 20230428060918 | 20230228 | VISIBER57 CORP. | These
unaudited financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among
other things, the realization of assets and the satisfaction of liabilities in the normal course of business. As reflected in the accompanying
unaudited financial statements, the Company had a net loss of $30,237 and $24,759 for the six months ended February 28, 2023 and 2022,
respectively. The working capital deficit was $380,935 as of February 28, 2023. The net cash generated from operating activities was
$0 for both the six months ended February 28, 2023 and 2022. These factors raise substantial doubt about the Company’s ability
to continue as a going concern for twelve months from the issuance of this report. | [
{
"currency_/_unit": "USD",
"end_character": 354,
"end_date_for_period": "2023-02-28",
"label": "earnings",
"start_character": 348,
"start_date_for_period": "2022-09-01",
"value": -30237
},
{
"currency_/_unit": "USD",
"end_character": 366,
"end_date_for_period": "2022-02-28",
"label": "earnings",
"start_character": 360,
"start_date_for_period": "2021-09-01",
"value": -24759
},
{
"currency_/_unit": "USD",
"end_character": 474,
"end_date_for_period": "2023-02-28",
"label": "XBRL-OOS",
"start_character": 467,
"start_date_for_period": "2023-02-28",
"value": 380935
}
] |
10-Q | 0001694028-23-000021 | 20230421160552 | 20230331 | Liberty Energy Inc. | Revenues from operating leases for the three months ended March 31, 2023 and 2022 were $8.6 million and $5.9 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 91,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 88,
"start_date_for_period": "2023-01-01",
"value": 8600000
},
{
"currency_/_unit": "USD",
"end_character": 108,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 105,
"start_date_for_period": "2022-01-01",
"value": 5900000
}
] |
10-Q | 0001493152-23-017266 | 20230515160121 | 20230331 | AMERICAN REBEL HOLDINGS INC | The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates
the recoverability of assets and the satisfaction of liabilities in the normal course of business. As noted above, the Company is in
the growth and acquisition stage and, accordingly, has not yet reached profitability from its operations. Since inception, the
Company has been engaged in financing activities and executing its business plan of operations and incurring costs and expenses
related to product development, branding, inventory buildup and product launch. As a result, the Company has continued to incur net
losses for the three months ended March 31, 2023, and 2022 of ($227,055)
and ($2,628,237),
respectively. The Company’s accumulated deficit was ($34,339,865)
as of March 31, 2023, and ($34,112,810)
as of December 31, 2022. The Company’s working capital was $6,477,127
as of March 31, 2023, compared to $6,678,562
as of December 31, 2022. The decrease in working capital from December 31, 2022, to March 31, 2023, is due to the Company incurring a net loss during the three
months ending March 31, 2023. Until recently the Company’s activities since inception have been sustained through equity/debt
financing and the continued usage of deferral of payments on accounts payable and other expenses. | [
{
"currency_/_unit": "USD",
"end_character": 727,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 720,
"start_date_for_period": "2023-01-01",
"value": -227055
},
{
"currency_/_unit": "USD",
"end_character": 744,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 735,
"start_date_for_period": "2022-01-01",
"value": -2628237
},
{
"currency_/_unit": "USD",
"end_character": 922,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 913,
"start_date_for_period": "2023-03-31",
"value": 6477127
},
{
"currency_/_unit": "USD",
"end_character": 967,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 958,
"start_date_for_period": "2022-12-31",
"value": 6678562
}
] |
10-Q | 0000769520-23-000009 | 20230511161213 | 20230401 | MIDDLEBY Corp | The company’s potentially dilutive securities consist of shares issuable on vesting of restricted stock grants computed using the treasury method and amounted to 2,000 and 6,000 for the three months ended April 1, 2023 and April 2, 2022, respectively. For the three months ended April 1, 2023 and April 2, 2022, the average market price of the company's common stock exceeded the exercise price of the Convertible Notes (as defined below) resulting in 781,000 and 1,688,000 diluted common stock equivalents to be included in the diluted net earnings per share, respectively. There have been no material conversions to date. See Note 12, Financing Arrangements for further details on the Convertible Notes. There were no anti-dilutive restricted stock grants excluded from common stock equivalents in any period presented. | [
{
"currency_/_unit": "shares",
"end_character": 167,
"end_date_for_period": "2023-04-01",
"label": "eps",
"start_character": 162,
"start_date_for_period": "2023-01-01",
"value": 2000
},
{
"currency_/_unit": "shares",
"end_character": 177,
"end_date_for_period": "2022-04-02",
"label": "eps",
"start_character": 172,
"start_date_for_period": "2022-01-02",
"value": 6000
},
{
"currency_/_unit": "shares",
"end_character": 459,
"end_date_for_period": "2023-04-01",
"label": "eps",
"start_character": 452,
"start_date_for_period": "2023-01-01",
"value": 781000
},
{
"currency_/_unit": "shares",
"end_character": 473,
"end_date_for_period": "2022-04-02",
"label": "eps",
"start_character": 464,
"start_date_for_period": "2022-01-02",
"value": 1688000
}
] |
10-Q | 0001591956-23-000012 | 20230511170539 | 20230331 | Sphere 3D Corp. | The Company has recurring losses from operations and incurred a net loss of approximately $3.5 million for the three months ended March 31, 2023. Management has projected that based on our hashing rate at March 31, 2023, cash on hand may not be sufficient to allow the Company to continue operations beyond the next 12 months if we are unable to raise additional funding for operations. We expect our working capital needs to increase in the future as we continue to expand and enhance our operations. Our ability to raise additional funds for working capital through equity or debt financings or other sources may depend on the financial success of our then current business and successful implementation of our key strategic initiatives, financial, economic and market conditions and other factors, some of which are beyond our control. No assurance can be given that we will be successful in raising the required capital at a reasonable cost and at the required times, or at all. Further equity financings may have a dilutive effect on shareholders and any debt financing, if available, may require restrictions to be placed on our future financing and operating activities. We require additional capital and if we are unsuccessful in raising that capital, we may not be able to continue our business operations in the cryptocurrency mining industry or we may be unable to advance our growth initiatives, either of which could adversely impact our business, financial condition and results of operations. | [
{
"currency_/_unit": "USD",
"end_character": 94,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 91,
"start_date_for_period": "2023-01-01",
"value": -3500000
}
] |
10-Q | 0000070318-23-000019 | 20230428160621 | 20230331 | TENET HEALTHCARE CORP | During the three months ended March 31, 2023, we recorded income tax expense of $84 million in on pre-tax income of $380 million compared to $99 million on pre-tax income of $378 million during the three months ended March 31, 2022. Our provision for income taxes during interim reporting periods is calculated by applying an estimate of the annual effective tax rate to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. In calculating “ordinary” income, non‑taxable income or loss attributable to noncontrolling interests was deducted from pre-tax income. | [
{
"currency_/_unit": "USD",
"end_character": 83,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 81,
"start_date_for_period": "2023-01-01",
"value": 84000000
},
{
"currency_/_unit": "USD",
"end_character": 120,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 117,
"start_date_for_period": "2023-01-01",
"value": 380000000
},
{
"currency_/_unit": "USD",
"end_character": 144,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 142,
"start_date_for_period": "2022-01-01",
"value": 99000000
},
{
"currency_/_unit": "USD",
"end_character": 178,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 175,
"start_date_for_period": "2022-01-01",
"value": 378000000
}
] |
10-Q | 0001493152-23-016640 | 20230512161607 | 20230331 | Sidus Space Inc. | For
the three months ended March 31, 2023 and 2022, Aurea’s net loss was $976 and $32,107 respectively. | [
{
"currency_/_unit": "USD",
"end_character": 77,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 74,
"start_date_for_period": "2023-01-01",
"value": 976
},
{
"currency_/_unit": "USD",
"end_character": 89,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 83,
"start_date_for_period": "2022-01-01",
"value": 32107
}
] |
10-Q | 0000798949-23-000021 | 20230511115039 | 20230331 | UNIT CORP | 1. The Company reviews available positive and negative evidence to assess the need for a valuation allowance against the Company's deferred tax assets. On the basis of this assessment, a full valuation allowance was recorded against the Company's net deferred tax assets in 2020 and maintained through December 31, 2022. The Company subsequently recorded net income attributable to Unit Corporation of $148.4 million and $60.6 million during 2022 and 2021, respectively. After considering these positive results, the resulting significant three-year cumulative income position, and other available positive and negative evidence, the Company determined that it is more likely than not that a portion of the net deferred tax assets would be realized. Accordingly, the Company released a portion of its valuation allowance contributing to a $94.7 million net change in the valuation allowance during the three months ended March 31, 2023 with a corresponding income tax benefit recorded in our unaudited condensed consolidated statements of operations. | [
{
"currency_/_unit": "USD",
"end_character": 408,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 403,
"start_date_for_period": "2022-01-01",
"value": 148400000
},
{
"currency_/_unit": "USD",
"end_character": 426,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 422,
"start_date_for_period": "2021-01-01",
"value": 60600000
},
{
"currency_/_unit": "USD",
"end_character": 844,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 840,
"start_date_for_period": "2023-01-01",
"value": -94700000
}
] |
10-Q | 0001790625-23-000072 | 20230515160800 | 20230331 | AgileThought, Inc. | For the three months ended March 31, 2023, the Company reported a nominal tax expense on a pretax loss of $38.1 million. The Company’s effective tax rate differs from the U.S. statutory rate of 21% due to losses incurred in jurisdictions for which no tax benefit is recognized. | [
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 107,
"start_date_for_period": "2023-01-01",
"value": -38100000
}
] |
10-Q | 0000059478-23-000162 | 20230427115656 | 20230331 | ELI LILLY & Co | Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March 31, 2023 and 2022, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 105,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 101,
"start_date_for_period": "2023-01-01",
"value": 25100000
},
{
"currency_/_unit": "USD",
"end_character": 123,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 119,
"start_date_for_period": "2022-01-01",
"value": 53200000
}
] |
10-Q | 0000059478-23-000162 | 20230427115656 | 20230331 | ELI LILLY & Co | Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $1.47 billion, primarily related to bebtelovimab, for the three months ended March 31, 2022. We did not have sales of our COVID-19 antibodies during the three months ended March 31, 2023. | [
{
"currency_/_unit": "USD",
"end_character": 150,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 146,
"start_date_for_period": "2022-01-01",
"value": 1470000000
}
] |
10-Q | 0001925531-23-000007 | 20230515144710 | 20230331 | New Mountain Guardian IV BDC, L.L.C. | Interest income, including amortization of premium and discount using the effective interest method, is recorded on the accrual basis and periodically assessed for collectability. Interest income also includes interest earned from cash on hand. Upon the prepayment of a loan or debt security, any prepayment penalties are recorded as part of interest income. The Company has loans and certain preferred equity investments in its portfolio that contain a payment-in-kind ("PIK") interest or dividend provision. PIK interest and dividends are accrued and recorded as income at the contractual rates, if deemed collectible. The PIK interest and dividends are added to the principal or share balances on the capitalization dates and are generally due at maturity or when redeemed by the issuer. For the three months ended March 31, 2023, the Company recognized PIK dividends from investments of $25 and PIK interest from investments of $93. | [
{
"currency_/_unit": "USD",
"end_character": 894,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 892,
"start_date_for_period": "2023-01-01",
"value": 25000
},
{
"currency_/_unit": "USD",
"end_character": 935,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 933,
"start_date_for_period": "2023-01-01",
"value": 93000
}
] |
10-Q | 0001840292-23-000021 | 20230510160648 | 20230331 | Heliogen, Inc. | The Company has evaluated whether there were conditions and events, considered in the aggregate, which raise substantial doubt as to the Company’s ability to continue as a going concern within one year after the original issuance date of the consolidated financial statements. During the three months ended March 31, 2023 and the year ended December 31, 2022, the Company incurred net losses of $10.5 million and $142.0 million, respectively. The Company expects to continue to generate operating losses in the next few years. | [
{
"currency_/_unit": "USD",
"end_character": 400,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 396,
"start_date_for_period": "2023-01-01",
"value": -10500000
},
{
"currency_/_unit": "USD",
"end_character": 419,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 414,
"start_date_for_period": "2022-01-01",
"value": -142000000
}
] |
10-Q | 0000921082-23-000041 | 20230425160352 | 20230331 | HIGHWOODS PROPERTIES, INC. | We generally lease our office properties to lessees in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance. Office properties owned by us that are under lease are primarily located in Atlanta, Charlotte, Nashville, Orlando, Pittsburgh, Raleigh, Richmond and Tampa and are leased to a wide variety of lessees across many industries. Our leases are operating leases and mostly range from three to 10 years. We recognized rental and other revenues related to operating lease payments of $209.4 million and $203.6 million during the three months ended March 31, 2023 and 2022, respectively. Included in these amounts are variable lease payments of $19.4 million and $17.4 million during the three months ended March 31, 2023 and 2022, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 580,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 575,
"start_date_for_period": "2023-01-01",
"value": 209400000
},
{
"currency_/_unit": "USD",
"end_character": 599,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 594,
"start_date_for_period": "2022-01-01",
"value": 203600000
},
{
"currency_/_unit": "USD",
"end_character": 739,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 735,
"start_date_for_period": "2023-01-01",
"value": 19400000
},
{
"currency_/_unit": "USD",
"end_character": 757,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 753,
"start_date_for_period": "2022-01-01",
"value": 17400000
}
] |
10-Q | 0001829126-23-004208 | 20230615205734 | 20230430 | Glidelogic Corp. | The
accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States
(“GAAP”), which contemplate continuation of the Company as a going concern. The Company had no revenues for the three
months ended April 30, 2023. The Company currently has not completed its efforts to establish a stabilized source of revenue sufficient
to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to
continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment
capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through
the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any
of its endeavors or become financially viable and continue as a going concern. | [
{
"currency_/_unit": "USD",
"end_character": 233,
"end_date_for_period": "2023-04-30",
"label": "revenues",
"start_character": 231,
"start_date_for_period": "2023-02-01",
"value": 0
}
] |
10-Q | 0001628280-23-015984 | 20230505070620 | 20230331 | FLUOR CORP | Segment profit in the 2023 Quarter included a $59 million (or $0.34 per share) charge for rework associated with subcontractor design errors, related schedule impacts and system integration testing timelines on the LAX Automated People Mover project. Intercompany revenue for our professional staffing business, excluded from the amounts shown above, was $69 million and $60 million for the 2023 Quarter and 2022 Quarter, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 49,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 47,
"start_date_for_period": "2023-01-01",
"value": 59000000
},
{
"currency_/_unit": null,
"end_character": 67,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 63,
"start_date_for_period": "2023-01-01",
"value": 0.34
},
{
"currency_/_unit": "USD",
"end_character": 358,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 356,
"start_date_for_period": "2023-01-01",
"value": 69000000
},
{
"currency_/_unit": "USD",
"end_character": 374,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 372,
"start_date_for_period": "2022-01-01",
"value": 60000000
}
] |
10-Q | 0001521945-23-000023 | 20230509180550 | 20230331 | Prospect Floating Rate & Alternative Income Fund, Inc. | The Company has certain investments in its portfolio that contain a PIK interest provision, which represents contractual interest or dividends that are added to the principal balance and recorded as income. For the three months ended March 31, 2023 and 2022, PIK interest included in interest income totaled $9,454 and $194, respectively. For the nine months ended March 31, 2023 and 2022, PIK interest included in interest income totaled $9,616 and $579, respectively. The Company stops accruing PIK interest when it is determined that PIK interest is no longer collectible. To maintain RIC tax | [
{
"currency_/_unit": "USD",
"end_character": 314,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 309,
"start_date_for_period": "2023-01-01",
"value": 9454
},
{
"currency_/_unit": "USD",
"end_character": 323,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 320,
"start_date_for_period": "2022-01-01",
"value": 194
},
{
"currency_/_unit": "USD",
"end_character": 445,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 440,
"start_date_for_period": "2022-07-01",
"value": 9616
},
{
"currency_/_unit": "USD",
"end_character": 454,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 451,
"start_date_for_period": "2021-07-01",
"value": 579
}
] |
10-Q | 0001479290-23-000072 | 20230509163400 | 20230331 | Revance Therapeutics, Inc. | We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development services to be provided for the development period. For revenue recognition purposes, the development period is estimated to be completed in 2026. It is possible that this period will change and is assessed at each reporting date. ASC Topic 606, Revenue from Contracts with Customers (ASC 606) requires that an entity include a constraint on the amount of variable consideration included in the transaction price. Variable consideration is considered “constrained” if there is a potential for significant reversal of cumulative revenue recognized. As part of the constraint evaluation, we considered numerous factors, including a potential shift in certain responsibilities between the two parties which would result in changes to the net cost sharing payments, for which outcomes are difficult to predict as of the date of this Report. As a result, no collaboration revenue is recognized from the biosimilar program for the three months ended March 31, 2023. We will continue to evaluate the variable transaction price and related revenue recognition in each reporting period and as the above uncertainties are resolved or other changes in circumstances occur. For the three months ended March 31, 2022, we recognized $3.6 million of revenue related to development services. | [
{
"currency_/_unit": "USD",
"end_character": 1369,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 1366,
"start_date_for_period": "2022-01-01",
"value": 3600000
}
] |
10-Q | 0001479290-23-000072 | 20230509163400 | 20230331 | Revance Therapeutics, Inc. | For the three months ended March 31, 2023, we recognized revenue of $0.1 million related to the Fosun License Agreement. For the three months ended March 31, 2022, no revenue was recognized from the Fosun License Agreement. | [
{
"currency_/_unit": "USD",
"end_character": 72,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 69,
"start_date_for_period": "2023-01-01",
"value": 100000
},
{
"currency_/_unit": "USD",
"end_character": 166,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 164,
"start_date_for_period": "2022-01-01",
"value": 0
}
] |
10-Q | 0001628280-23-015294 | 20230503172629 | 20230331 | Altice USA, Inc. | For the three months ended March 31, 2023, the Company recorded a tax expense of $30,372 on pre-tax income of $61,542, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The higher tax rate was primarily due to the impact of certain non-deductible expenses, state tax expense, and tax deficiencies on share-based compensation. | [
{
"currency_/_unit": "USD",
"end_character": 88,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 82,
"start_date_for_period": "2023-01-01",
"value": 30372000
},
{
"currency_/_unit": "USD",
"end_character": 117,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 111,
"start_date_for_period": "2023-01-01",
"value": 61542000
}
] |
10-Q | 0001628280-23-015294 | 20230503172629 | 20230331 | Altice USA, Inc. | For the three months ended March 31, 2022, the Company recorded a tax expense of $82,846 on pre-tax income of $284,987, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The higher tax rate was due to the impact of certain non-deductible expenses and state tax expense. | [
{
"currency_/_unit": "USD",
"end_character": 88,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 82,
"start_date_for_period": "2022-01-01",
"value": 82846000
},
{
"currency_/_unit": "USD",
"end_character": 118,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 111,
"start_date_for_period": "2022-01-01",
"value": 284987000
}
] |
10-Q | 0000096223-23-000017 | 20230410165722 | 20230228 | Jefferies Financial Group Inc. | Represents dividends declared during the period on participating securities plus an allocation of undistributed earnings to participating securities. Net losses are not allocated to participating securities. Participating securities represent restricted stock and RSUs for which requisite service has not yet been rendered and amounted to weighted average shares of 676,000 and 1,571,000 for the three months ended February 28, 2023 and 2022, respectively. Dividends declared on participating securities were not material during the three months ended February 28, 2023 and 2022. Undistributed earnings are allocated to participating securities based upon their right to share in earnings if all earnings for the period had been distributed. | [
{
"currency_/_unit": "shares",
"end_character": 373,
"end_date_for_period": "2023-02-28",
"label": "eps",
"start_character": 366,
"start_date_for_period": "2022-12-01",
"value": 676000
},
{
"currency_/_unit": "shares",
"end_character": 387,
"end_date_for_period": "2022-02-28",
"label": "eps",
"start_character": 378,
"start_date_for_period": "2021-12-01",
"value": 1571000
}
] |
10-Q | 0001140361-23-023519 | 20230508170118 | 20230331 | SOUTH PLAINS FINANCIAL, INC. | The Company leases certain facilities and office space under operating lease agreements to outside parties. Operating lease income for the three months ended March
31, 2023, and 2022 was $204 thousand and $216 thousand, respectively and is included in occupancy and equipment,
net in the consolidated statements of comprehensive income (loss). | [
{
"currency_/_unit": "USD",
"end_character": 205,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 202,
"start_date_for_period": "2023-01-01",
"value": 204000
},
{
"currency_/_unit": "USD",
"end_character": 223,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 220,
"start_date_for_period": "2022-01-01",
"value": 216000
}
] |
10-Q | 0001618921-23-000043 | 20230627160417 | 20230531 | Walgreens Boots Alliance, Inc. | Due to the anti-dilutive effect resulting from the reported net loss, an incremental 3.3 million of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the nine months ended May 31, 2023. | [
{
"currency_/_unit": "shares",
"end_character": 88,
"end_date_for_period": "2023-05-31",
"label": "eps",
"start_character": 85,
"start_date_for_period": "2022-09-01",
"value": 3300000
}
] |
10-Q | 0001731289-23-000076 | 20230509110055 | 20230331 | Nikola Corp | The consolidated statements of operations include $0.4 million of service and other revenues and $23.8 million of operating loss related to Romeo for the three months ended March 31, 2023. | [
{
"currency_/_unit": "USD",
"end_character": 54,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 51,
"start_date_for_period": "2022-10-14",
"value": 400000
},
{
"currency_/_unit": "USD",
"end_character": 102,
"end_date_for_period": "2022-12-31",
"label": "ebit",
"start_character": 98,
"start_date_for_period": "2022-10-14",
"value": -23800000
}
] |
10-Q | 0001493152-23-017298 | 20230515160620 | 20230331 | AG Acquisition Group III, Inc. | Since
the inception of the Company through March 31, 2023, the Company has not generated cash or revenue. For the three and nine months ended
March 31, 2023, the Company incurred a net loss of $2,550 and $13,050, respectively. For the nine months ended March 31, 2023, the Company
used net cash in operating activities of $10,500. The Company had working capital deficiency of $2,340 as of March 31, 2023. The Company’s
continuation as a going concern is dependent on its ability to obtain additional financing from its stockholders or other sources, as
may be required, to meet its financial obligations as they become due. | [
{
"currency_/_unit": "USD",
"end_character": 199,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 194,
"start_date_for_period": "2023-01-01",
"value": -2550
},
{
"currency_/_unit": "USD",
"end_character": 211,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 205,
"start_date_for_period": "2022-07-01",
"value": -13050
},
{
"currency_/_unit": "USD",
"end_character": 329,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 323,
"start_date_for_period": "2022-07-01",
"value": -10500
},
{
"currency_/_unit": "USD",
"end_character": 383,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 378,
"start_date_for_period": "2023-03-31",
"value": 2340
}
] |
10-Q | 0001049521-23-000009 | 20230509161610 | 20230331 | MERCURY SYSTEMS INC | The Company recorded an income tax (benefit) provision of $(10,446) and $2,102 on a (loss) income before income taxes of $(5,290) and $6,241 for the third quarters ended March 31, 2023 and April 1, 2022, respectively. The Company recorded an income tax (benefit) provision of $(13,619) and $1,506 on a loss before income taxes of $33,718 and $4,134 for the nine months ended March 31, 2023 and April 1, 2022, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 66,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 60,
"start_date_for_period": "2022-12-31",
"value": -10446000
},
{
"currency_/_unit": "USD",
"end_character": 78,
"end_date_for_period": "2022-04-01",
"label": "XBRL-OOS",
"start_character": 73,
"start_date_for_period": "2022-01-01",
"value": 2102000
},
{
"currency_/_unit": "USD",
"end_character": 128,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 123,
"start_date_for_period": "2022-12-31",
"value": -5290000
},
{
"currency_/_unit": "USD",
"end_character": 140,
"end_date_for_period": "2022-04-01",
"label": "earnings",
"start_character": 135,
"start_date_for_period": "2022-01-01",
"value": 6241000
},
{
"currency_/_unit": "USD",
"end_character": 284,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 278,
"start_date_for_period": "2022-07-02",
"value": -13619000
},
{
"currency_/_unit": "USD",
"end_character": 296,
"end_date_for_period": "2022-04-01",
"label": "XBRL-OOS",
"start_character": 291,
"start_date_for_period": "2021-07-03",
"value": 1506000
},
{
"currency_/_unit": "USD",
"end_character": 337,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 331,
"start_date_for_period": "2022-07-02",
"value": -33718000
},
{
"currency_/_unit": "USD",
"end_character": 348,
"end_date_for_period": "2022-04-01",
"label": "earnings",
"start_character": 343,
"start_date_for_period": "2021-07-03",
"value": -4134000
}
] |
10-Q | 0001220754-23-000024 | 20230503214746 | 20230331 | ModivCare Inc | The Company's gross share of its Matrix's operations for the three months ended March 31, 2023 and March 31, 2022 was income of $1.9 million and income of $0.8 million, respectively, which is presented net of tax on the unaudited condensed consolidated statements of operations for income of $1.4 million and income of $0.5 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 132,
"end_date_for_period": "2023-03-31",
"label": "ebit",
"start_character": 129,
"start_date_for_period": "2023-01-01",
"value": 1900000
},
{
"currency_/_unit": "USD",
"end_character": 159,
"end_date_for_period": "2022-03-31",
"label": "ebit",
"start_character": 156,
"start_date_for_period": "2022-01-01",
"value": 800000
},
{
"currency_/_unit": "USD",
"end_character": 296,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 293,
"start_date_for_period": "2023-01-01",
"value": 1400000
},
{
"currency_/_unit": "USD",
"end_character": 323,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 320,
"start_date_for_period": "2022-01-01",
"value": 500000
}
] |
10-Q | 0001140361-23-025726 | 20230519154644 | 20230331 | Home Federal Bancorp, Inc. of Louisiana | Earnings per share are computed based upon
the weighted average number of common shares outstanding during the period. The Company’s basic and diluted earnings per share were $1.48
and $1.41, respectively, for the nine months ended March 31, 2023 compared to basic and diluted earnings per share of $1.18 and $1.10, respectively, for the
nine months ended March 31, 2022. The Company’s basic and diluted earnings per share were $0.35 and $0.34, respectively, for the three months ended March 31, 2023 compared to basic and diluted earnings per share of $0.39 and $0.37, respectively, for the
three months ended March 31, 2022. | [
{
"currency_/_unit": null,
"end_character": 188,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 184,
"start_date_for_period": "2022-07-01",
"value": 1.48
},
{
"currency_/_unit": null,
"end_character": 206,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 202,
"start_date_for_period": "2022-07-01",
"value": 1.4100000000000001
},
{
"currency_/_unit": null,
"end_character": 320,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 316,
"start_date_for_period": "2021-07-01",
"value": 1.18
},
{
"currency_/_unit": null,
"end_character": 330,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 326,
"start_date_for_period": "2021-07-01",
"value": 1.1
},
{
"currency_/_unit": null,
"end_character": 458,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 454,
"start_date_for_period": "2023-01-01",
"value": 0.35000000000000003
},
{
"currency_/_unit": null,
"end_character": 468,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 464,
"start_date_for_period": "2023-01-01",
"value": 0.34
},
{
"currency_/_unit": null,
"end_character": 583,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 579,
"start_date_for_period": "2022-01-01",
"value": 0.39
},
{
"currency_/_unit": null,
"end_character": 593,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 589,
"start_date_for_period": "2022-01-01",
"value": 0.37
}
] |
10-Q | 0001140361-23-025726 | 20230519154644 | 20230331 | Home Federal Bancorp, Inc. of Louisiana | Earnings per share are computed based upon
the weighted average number of common shares outstanding during the period. The Company’s basic and diluted earnings per share were $1.48
and $1.41, respectively, for the nine months ended March 31, 2023 compared to basic and diluted earnings per share of $1.18 and $1.10, respectively, for the
nine months ended March 31, 2022. The Company’s basic and diluted earnings per share were $0.35 and $0.34, respectively, for the three months ended March 31, 2023 compared to basic and diluted earnings per share of $0.39 and $0.37, respectively, for the
three months ended March 31, 2022. | [
{
"currency_/_unit": null,
"end_character": 188,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 184,
"start_date_for_period": "2022-07-01",
"value": 1.48
},
{
"currency_/_unit": null,
"end_character": 206,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 202,
"start_date_for_period": "2022-07-01",
"value": 1.4100000000000001
},
{
"currency_/_unit": null,
"end_character": 320,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 316,
"start_date_for_period": "2021-07-01",
"value": 1.18
},
{
"currency_/_unit": null,
"end_character": 330,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 326,
"start_date_for_period": "2021-07-01",
"value": 1.1
},
{
"currency_/_unit": null,
"end_character": 458,
"end_date_for_period": "2023-03-31",
"label": "eps",
"start_character": 454,
"start_date_for_period": "2023-01-01",
"value": 0.35000000000000003
},
{
"currency_/_unit": null,
"end_character": 468,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 464,
"start_date_for_period": "2023-01-01",
"value": 0.34
},
{
"currency_/_unit": null,
"end_character": 583,
"end_date_for_period": "2022-03-31",
"label": "eps",
"start_character": 579,
"start_date_for_period": "2022-01-01",
"value": 0.39
},
{
"currency_/_unit": null,
"end_character": 593,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 589,
"start_date_for_period": "2022-01-01",
"value": 0.37
}
] |
10-Q | 0000085961-23-000102 | 20230426153408 | 20230331 | RYDER SYSTEM INC | The non-lease revenue from maintenance services related to our ChoiceLease product is recognized in "Lease & related maintenance and rental revenue" in the Condensed Consolidated Statements of Earnings. For the three months ended March 31, 2023 and 2022, we recognized $243 million and $257 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 273,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 270,
"start_date_for_period": "2023-01-01",
"value": 243000000
},
{
"currency_/_unit": "USD",
"end_character": 290,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 287,
"start_date_for_period": "2022-01-01",
"value": 257000000
}
] |
10-Q | 0001040971-23-000020 | 20230505172506 | 20230331 | SL GREEN REALTY CORP | We are entitled to receive fees for providing management, leasing, construction supervision and asset management services to certain of our joint ventures. We earned $4.9 million and $6.2 million from these services, net of our ownership share of the joint ventures, for the three months ended March 31, 2023 and 2022, respectively. In addition, we have the ability to earn incentive fees based on the ultimate financial performance of certain of the joint venture properties. | [
{
"currency_/_unit": "USD",
"end_character": 170,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 167,
"start_date_for_period": "2023-01-01",
"value": 4900000
},
{
"currency_/_unit": "USD",
"end_character": 187,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 184,
"start_date_for_period": "2022-01-01",
"value": 6200000
}
] |
10-Q | 0001781870-23-000007 | 20230512153914 | 20230331 | New Mountain Guardian III BDC, L.L.C. | Interest income, including amortization of premium and discount using the effective interest method, is recorded on the accrual basis and periodically assessed for collectability. Interest income also includes interest earned from cash on hand. Upon the prepayment of a loan or debt security, any prepayment penalties are recorded as part of interest income. The Company has loans and certain preferred equity investments in its portfolio that contain a payment-in-kind ("PIK") interest or dividend provision. PIK interest and dividends are accrued and recorded as income at the contractual rates, if deemed collectible. The PIK interest and dividends are added to the principal or share balances on the capitalization dates and are generally due at maturity or when redeemed by the issuer. For the three months ended March 31, 2023 and March 31, 2022, the Company recognized PIK interest from investments of $2,631 and $1,583, respectively, and PIK dividends from investments of $2,336 and $1,814, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 915,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 910,
"start_date_for_period": "2023-01-01",
"value": 2631000
},
{
"currency_/_unit": "USD",
"end_character": 926,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 921,
"start_date_for_period": "2022-01-01",
"value": 1583000
},
{
"currency_/_unit": "USD",
"end_character": 986,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 981,
"start_date_for_period": "2023-01-01",
"value": 2336000
},
{
"currency_/_unit": "USD",
"end_character": 997,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 992,
"start_date_for_period": "2022-01-01",
"value": 1814000
}
] |
10-Q | 0001493152-23-017001 | 20230515100044 | 20230331 | Processa Pharmaceuticals, Inc. | We
have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an
accumulated deficit of $68.3
million at March 31, 2023. During the three months ended March 31, 2023, we generated a net loss of $4.0
million and we expect to continue to generate operating losses and negative cash flow from operations for the foreseeable
future. Based on our current plans, we believe our current cash balances are adequate for at least the next twelve months. Our
ability to execute our longer-term operating plans, including future clinical trials for our portfolio of drugs depend on
our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the
necessary funding in the future when necessary. | [
{
"currency_/_unit": "USD",
"end_character": 156,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 152,
"start_date_for_period": "2023-03-31",
"value": -68300000
},
{
"currency_/_unit": "USD",
"end_character": 261,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 258,
"start_date_for_period": "2023-01-01",
"value": -4000000
}
] |
10-Q | 0001635650-23-000033 | 20230504161544 | 20230331 | Green Plains Partners LP | Revenue from Green Plains Trade Group was $19.7 million and $18.1 million for the three months ended March 31, 2023 and 2022, respectively, which exceeds 10% of the partnership’s total revenue. | [
{
"currency_/_unit": "USD",
"end_character": 47,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 43,
"start_date_for_period": "2023-01-01",
"value": 19700000
},
{
"currency_/_unit": "USD",
"end_character": 65,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 61,
"start_date_for_period": "2022-01-01",
"value": 18100000
}
] |
10-Q | 0000016058-23-000036 | 20230427100807 | 20230331 | CACI INTERNATIONAL INC /DE/ | Aggregate net changes in estimates for the three and nine months ended March 31, 2023 reflected an increase to income before income taxes of $5.3 million ($0.17 per diluted share) and | [
{
"currency_/_unit": "USD",
"end_character": 145,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 142,
"start_date_for_period": "2023-01-01",
"value": 5300000
},
{
"currency_/_unit": null,
"end_character": 160,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 156,
"start_date_for_period": "2023-01-01",
"value": 0.17
}
] |
10-Q | 0000016058-23-000036 | 20230427100807 | 20230331 | CACI INTERNATIONAL INC /DE/ | $16.8 million ($0.53 per diluted share), respectively, compared with $13.0 million ($0.40 per diluted share) and | [
{
"currency_/_unit": "USD",
"end_character": 5,
"end_date_for_period": "2023-03-31",
"label": "earnings",
"start_character": 1,
"start_date_for_period": "2022-07-01",
"value": 16800000
},
{
"currency_/_unit": null,
"end_character": 20,
"end_date_for_period": "2023-03-31",
"label": "XBRL-OOS",
"start_character": 16,
"start_date_for_period": "2022-07-01",
"value": 0.53
},
{
"currency_/_unit": "USD",
"end_character": 74,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 70,
"start_date_for_period": "2022-01-01",
"value": 13000000
},
{
"currency_/_unit": null,
"end_character": 89,
"end_date_for_period": "2022-03-31",
"label": "XBRL-OOS",
"start_character": 85,
"start_date_for_period": "2022-01-01",
"value": 0.4
}
] |
10-Q | 0001628280-23-017775 | 20230512112756 | 20230331 | Nuveen Global Cities REIT, Inc. | Rental income is recognized on a straight-line basis. The leases do not have material variable payments, material residual value guarantees or material restrictive covenants. Rental income for the three months ended March 31, 2023 and 2022 was $42.3 million and $21.7 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 249,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 245,
"start_date_for_period": "2023-01-01",
"value": 42300000
},
{
"currency_/_unit": "USD",
"end_character": 267,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 263,
"start_date_for_period": "2022-01-01",
"value": 21700000
}
] |
10-Q | 0001287032-23-000161 | 20230509161524 | 20230331 | PROSPECT CAPITAL CORP | During the three months ended March 31, 2023 and March 31, 2022, we received payments of $2,316 and $2,276, respectively, from our portfolio companies for managerial assistance and subsequently remitted these amounts to Prospect Administration. During the nine months ended March 31, 2023 and March 31, 2022, we received payments of $7,008 and $5,946, respectively, from our portfolio companies for managerial assistance and subsequently remitted these amounts to Prospect Administration. | [
{
"currency_/_unit": "USD",
"end_character": 95,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 90,
"start_date_for_period": "2023-01-01",
"value": 2316000
},
{
"currency_/_unit": "USD",
"end_character": 106,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 101,
"start_date_for_period": "2022-01-01",
"value": 2276000
},
{
"currency_/_unit": "USD",
"end_character": 340,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 335,
"start_date_for_period": "2022-07-01",
"value": 7008000
},
{
"currency_/_unit": "USD",
"end_character": 351,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 346,
"start_date_for_period": "2021-07-01",
"value": 5946000
}
] |
10-Q | 0001781755-23-000014 | 20230509162349 | 20230331 | BRP Group, Inc. | During the three months ended March 31, 2023, the Insurance Advisory Solutions Operating Group recorded intercompany commissions and fees from activity with the UCTS Operating Group of $0.4 million; the UCTS Operating Group recorded intercompany commissions and fees from activity with the Mainstreet Insurance Solutions Operating Group and itself of $12.6 million; and the Mainstreet Insurance Solutions Operating Group recorded intercompany commissions and fees from activity with all Operating Groups of $0.9 million. These intercompany commissions and fees are eliminated through Corporate and Other. | [
{
"currency_/_unit": "USD",
"end_character": 189,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 186,
"start_date_for_period": "2023-01-01",
"value": 400000
},
{
"currency_/_unit": "USD",
"end_character": 356,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 352,
"start_date_for_period": "2023-01-01",
"value": 12600000
},
{
"currency_/_unit": "USD",
"end_character": 511,
"end_date_for_period": "2023-03-31",
"label": "revenues",
"start_character": 508,
"start_date_for_period": "2023-01-01",
"value": 900000
}
] |
10-Q | 0001781755-23-000014 | 20230509162349 | 20230331 | BRP Group, Inc. | During the three months ended March 31, 2022, the Insurance Advisory Solutions Operating Group recorded intercompany commissions and fees from activity with the UCTS Operating Group of $0.3 million; the UCTS Operating Group recorded intercompany commissions and fees from activity with itself of $0.1 million; and the Mainstreet Insurance Solutions Operating Group recorded intercompany commissions and fees from activity with all Operating Groups of $0.6 million. These intercompany commissions and fees are eliminated through Corporate and Other. | [
{
"currency_/_unit": "USD",
"end_character": 189,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 186,
"start_date_for_period": "2022-01-01",
"value": 300000
},
{
"currency_/_unit": "USD",
"end_character": 300,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 297,
"start_date_for_period": "2022-01-01",
"value": 100000
},
{
"currency_/_unit": "USD",
"end_character": 455,
"end_date_for_period": "2022-03-31",
"label": "revenues",
"start_character": 452,
"start_date_for_period": "2022-01-01",
"value": 600000
}
] |
10-Q | 0001185348-23-000019 | 20230508180119 | 20230331 | PRA GROUP INC | The Company incurred a net loss from operations of $33.6 million for the three months ended March 31, 2023. The Company requested and was granted a one-time prospective waiver by lenders under each of its credit facilities prior to the date the Company was required to report and certify compliance with the covenant requiring the Company to maintain positive consolidated income from operations. The effect of granting the waiver prior to certification date for such compliance resulted in the Company maintaining compliance with the applicable financial covenants of its credit facilities as of March 31, 2023. | [
{
"currency_/_unit": "USD",
"end_character": 56,
"end_date_for_period": "2023-03-31",
"label": "ebit",
"start_character": 52,
"start_date_for_period": "2023-01-01",
"value": -33600000
}
] |
Subsets and Splits